Lundbeck Looks To Pipeline As Generic Competition Hits
Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.
You may also be interested in...
Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.